Sarepta Therapeutics, Inc. (SRPT)

Market Cap	2.37B
Revenue (ttm)	2.48B
Net Income (ttm)	-57.96M
Shares Out	97.71M
EPS (ttm)	-0.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,931,171
Open	23.48
Previous Close	23.50
Day's Range	23.27 - 24.38
52-Week Range	10.42 - 138.81
Beta	0.50
Analysts	Hold
Price Target	36.56 (+50.7%)
Earnings Date	Nov 3, 2025

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 1997
• Employees: 1,372
• Stock Exchange: NASDAQ
• Ticker Symbol: SRPT
• Website: https://www.sarepta.com

Analyst Summary

According to 30 analysts, the average rating for SRPT stock is "Hold." The 12-month stock price target is $36.56, which is an increase of 50.70% from the latest price.

Price Target

$36.56

(50.70% upside)

Analyst Consensus: Hold